Ginkgo Bioworks - DNA Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price objectives for Ginkgo Bioworks' stock. Their DNA share price forecasts range from $3.00 to $12.00. On average, they expect the company's share price to reach $5.92 in the next year. This suggests a possible upside of 202.0% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA stock has increased by 16.0% and is now trading at $1.96.
View the best growth stocks for 2023 here.

Ginkgo Bioworks saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 126,250,000 shares, an increase of 10.5% from the December 15th total of 114,290,000 shares. Based on an average daily volume of 24,280,000 shares, the short-interest ratio is presently 5.2 days. Currently, 12.5% of the company's shares are short sold.
View Ginkgo Bioworks' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our DNA earnings forecast.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) issued its quarterly earnings data on Monday, November, 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by $0.15. The firm had revenue of $66.40 million for the quarter, compared to analysts' expectations of $54.28 million. Ginkgo Bioworks had a negative net margin of 668.49% and a negative trailing twelve-month return on equity of 85.90%.

Ginkgo Bioworks updated its FY 2022 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$480.00 million, compared to the consensus revenue estimate of $470.79 million.

Ginkgo Bioworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "DNA."

Ginkgo Bioworks' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.59%), ARK Investment Management LLC (7.44%), Sumitomo Mitsui Trust Holdings Inc. (1.93%), Equitec Proprietary Markets LLC (0.21%), Bourgeon Capital Management LLC (0.02%) and Polianta Ltd (0.02%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk and Reshma P Shetty.
View institutional ownership trends.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNA stock can currently be purchased for approximately $1.96.

Ginkgo Bioworks (NYSE:DNA) has a market capitalization of $3.80 billion and generates $313.84 million in revenue each year. The company earns $-1,830,050,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

The company employs 641 workers across the globe.

Ginkgo Bioworks' mailing address is 955 Fifth Avenue, New York NY, 10075. The official website for the company is www.eagleequityptnrs.com. The company can be reached via phone at 877-442-5362 or via email at investors@ginkgobioworks.com.